Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations

Abstract excerpt

MRD monitoring has increasingly emerged as a pivotal dynamic biomarker in acute myeloid leukemia (AML), offering additional prognostic value beyond baseline disease genetics and standard response assessment [ 1 , 2 ]. While MRD evaluation using reverse-transcription quantitative polymerase chain reaction (RT-qPCR) and multiparametric flow cytometry (MFC) has been well established in patients undergoing intensive...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Acute Myeloid Leukemia Research
• Share to Myeloproliferative Neoplasms: Diagnosis and Treatment